Zuardi et al. (1991) tested the effects of CBD and haloperidol in a model which predicts anti-psychotic activity in rats. Apomorphine induces stereotyped sniffing and biting. Both drugs decreased the frequency of these behaviors. CBD did not induce catalepsy, even at very high doses, although haloperidol induced catalepsy. The authors conclude that CBD has a pharmacological profile similar to the atypical antipsychotic drugs.
Musty et al. (2000) tested the effects of the of the CB 1 receptor antagonist SR141716 in two animal models of schizophrenia. In the first model, ibotenic acid lesions of the hippocampus were made in neonatal rats, which results in a brain degeneration pattern similar to that observed in schizophrenics, as well as abnormal play behavior in an anxiety-provoking environment. In the second model, ketamine-induced enhancement of pre-pulse inhibition was tested. In both of these tests, SR141716 reversed the abnormal behavior. These findings in animal models are consistent with the hypothesis that CBX receptor antagonists have antipsychotic activity.
Was this article helpful?